We use cookies on our website to track and enhance your user experience. For more information or to update your cookie settings, please refer to our privacy policy.

Accept Decline

SureSeq myPanel™ NGS Custom Colorectal Cancer Panel

Product types:
Applications:

Choose your perfect colorectal NGS panel from our range of fully tested and optimised panel content. Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs.

Find out more

For more information about any OGT product or service, please contact us.

Email: contact@ogt.com
Phone: +44 (0)1865 856800 (US: 914 467 5285)

Overview

Choose your ideal colorectal cancer NGS panel from our range of fully tested and optimised NGS panel content. Simply mix and match the genes or individual exons you require to get the most out of your sequencing runs. Use in conjunction with the SureSeq FFPE DNA Repair Mix* for improved NGS library yields, %OTR and mean target coverage from challenging FFPE derived samples.

SureSeq myPanel offers:

  • Hybridisation-based enrichment delivering unparalleled coverage uniformity- detect low frequency colorectal cancer variants consistently with confidence and minimise the requirement for supplementary fill-in with Sanger sequencing
  • Pre-optimised panels that meet your technical requirements and work with your samples - no more lengthy in-house optimisation, decreasing assay development time
  • Bespoke panel content - sequence only what’s relevant for your cancer research, increase throughput and save on sequencing reagents
  • Panel content designed with experts and from current literature to target all relevant regions including intronic and splice sites - get the most comprehensive insight into disease-driving mutations

Getting started with your next SureSeq myPanel Colrectal Panel could not be simpler...

Let us know your cancer(s) of interest and allow Oxford Gene Technology to put our expertise to work in advancing your cancer research.

Design your panel now

Ordering Information

Product Contents Cat. No. Price
SureSeq myPanel NGS Custom Colorectal Panel Enrichment baits; SureSeq Interpret Software various Get a quote

 

SureSeq: For research use only; not for use in diagnostic procedures.

Details

Colorectal cancer (CRC) is the third most common cancer in men (746,000 cases,10.0% of the total) and the second in women (614,000 cases, 9.2% of the total) worldwide1. Next generation sequencing (NGS) has enabled the simultaneous study of mutations in high-penetrance colorectal cancer genes. These include KRAS, APC and TP53 as well as more moderate-risk genes such as ERBB2, PTEN and BRAF.2

Design your panel now

Superior Coverage Uniformity

KRAS mutations are found in approximately 35-45% of colorectal cancers with around 80% occurring in codon 12 and 15% in codon 13 of exon 2; other commonly reported mutations are found in exons 3 and 43. The tumor suppressor gene APC plays an important role in CRC development. Absence of the APC protein leads to accumulation of betacatenin in the cytoplasm, which may contribute to tumour progression. 60% of all somatic mutations in APC occur within the mutation cluster region between codons 1286 and 1513 on exon 154. Figures 1a, b, c and 2 illustrate the superior uniformity of coverage of these key genomic regions.

Figure 1a, 1b and 1c

Figure 1 a, b, c. KRAS exons 2, 3 and 4 coverage.

Figure 2Figure 2. APC exon 15 coverage. Depth of coverage per base (grey). Targeted region (green). Gene coding region as defined by RefSeq (blue). GC percentage (red).

Approximately 8-15% of colorectal cancers involve mutations in the BRAF gene, with up to 90% of these a result of a mutation at V600E, located on exon 155. In TP53, another frequently mutated cancer gene, point mutations are predominantly located in exons 5-82, however sequencing is often hampered by the GC-rich content, which can lead to technical challenges in assay design and analysis. OGT’s innovative bait design overcomes this issue, offering a high level of uniform coverage for these difficult genes to sequence in FFPE samples, Figure 4.

Figure 3

Figure 4

Illustration of the excellent uniformity of coverage of (Figure 3) BRAF exon 15 and TP53 exons 3 - 9 (Figure 4). Depth of coverage per base (grey). Targeted region (green). Gene coding region as defined by RefSeq (blue). GC percentage (red).

Select from any of the following myPanel colorectal whole gene or exonic content below:

APC CDH1 ERBB2 KRAS MSH6 PIK3CA STK11
BRAF CHEK2 HRAS MET NRAS PTEN TP53

 

Getting started with your next SureSeq myPanel Custom Cancer Panel could not be simpler...

SureSeq myPanel™

Talk to us about your custom colorectal NGS panel requirements and let our expertise work in helping advance your cancer research.

Design your panel now

Ordering Information

Product Contents Cat. No. Price
SureSeq myPanel NGS Custom Colorectal Panel Enrichment baits; SureSeq Interpret Software Various Get a quote
SureSeq FFPE DNA Repair Mix* Enzyme, mix and buffers sufficient for 16 FFPE DNA samples 500079 Get a quote
SureSeq NGS Library Preparation Kit (16) Bundle of 1 x library preparation kit (16) containing adaptors, PCR primers and enzymes sufficient for 16 samples and 1 x SureSeq NGS Index Kit – Collection A 500070 Get a quote
SureSeq NGS Library Preparation Kit (48)  Bundle of 3 x library preparation kit (16), containing adaptors, PCR primers and enzymes sufficient for 48 samples and 1 x SureSeq NGS Index Kit – Collection B 500073 Get a quote
SureSeq NGS Index Kit - Collection A (16) 16 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (16)] 500071 Get a quote
SureSeq NGS Index Kit - Collection B (48) 48 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (48)] 500072 Get a quote

 

*The SureSeq FFPE DNA Repair Mix can only be purchased in conjunction with SureSeq NGS panels, not as a standalone product.

References

1. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
2. Han et al, PLoS One. 2013; 8(5): e64271
3. Tan et al, World J Gastroenterol. 2012 Oct 7; 18(37): 5171–51804
4. More, et al, Hum Mol Genet (1992) 1 (4): 229-233
5. https://www.mycancergenome.org/content/disease/colorectal-cancer/braf/54/

SureSeq: For research use only; not for use in diagnostic procedures.

Resources

Application note

Product profile

Brochure

Gene list

Lab Programme

Handbook

Poster

Catalogue

Flyer

White paper

<  Return to products Back to top ↑